Addus HomeCare (ADUS, Health Care Services) Stock Valuation & Fair Value Fairly valued
Addus HomeCare (ADUS, Health Care Services) trades at a blended P/E of 17.2, about 21% below its historical normal valuation, with a forward growth estimate of 7.6% and a PEG of 2.27. Analysts' one-year estimates have been hit 73% of the time. Priced at its historical normal P/E of 21.7 on the same blended earnings, the 2026-09-18 close of $117.07 corresponds to about $148 a share. This is a valuation reference, not a price target.
The Street vs SeerForecast
Wall Street's mean price target for ADUS is $133.54 across 13 analysts, 16.2% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been fairly valued since 2026-07-31.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Frequently asked questions
Is Addus HomeCare stock overvalued?
At a blended P/E of 17.2 versus its historical normal P/E of 21.7, Addus HomeCare trades about 21% below its typical valuation, with a PEG of 2.27 on 7.6% forward growth. tickerseer currently rates it fairly valued.
What is Addus HomeCare's fair value and PEG?
Addus HomeCare trades at a blended P/E of 17.2 against a historical normal P/E of 21.7, a PEG of 2.27, and a forward growth estimate of 7.6%. Priced at its historical normal P/E of 21.7 on the same blended earnings, the 2026-09-18 close of $117.07 corresponds to about $148 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Addus HomeCare changed?
tickerseer's rating has been fairly valued since 2026-07-31.
What is the analyst price target for Addus HomeCare?
The mean Wall Street price target for Addus HomeCare is $133.54 across 13 analysts, 16.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health Care Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.